The Ataxia Telangiectasia Mutated Kinase Pathway Regulates IL-23 Expression by Human Dendritic Cells

Qunwei Wang(Nanjing University of Aeronautics and Astronautics), Andrew M. Jackson(University of Nottingham), Hester Franks(University of Nottingham), Poulam M. Patel(Nottingham University Hospitals NHS Trust), Anna Małecka(University of Nottingham), Michael J. Gough(Providence Portland Medical Center), Mohamed El Refaee(University of Nottingham), S. Lax(University of Nottingham), Ian Spendlove(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Sabaria Shah(University of Nottingham), Claire Seedhouse(University of Nottingham)
The Journal of Immunology
March 5, 2013
10.4049/jimmunol.1201484
Cited by 24

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
|The Lancet Oncology|2015|282